Lyell Immunopharma Announces Participation in March Investor Conferences
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern TimeLeerink Annual Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida; fireside chat at 10:00am Eastern TimeCitizens Life Science Conference on Tuesday, March 10, 2026, in Miami, Florida; fireside chat at 11:55am Eastern Time A live webcast of each presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following each live presentation, a replay of the webcast will be available on the Company's website following the presentat
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaGlobeNewswire
- Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]Seeking Alpha
- Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma (NASDAQ:LYEL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.MarketBeat
- Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewswire
LYEL
Sec Filings
- 2/12/26 - Form 4
- 2/12/26 - Form 4
- 2/12/26 - Form 4
- LYEL's page on the SEC website